Sign in
Taking peopleNo phase

Comparing MRI image sharpness for diagnosing giant cell arteritis

Compares several MRI scan types for detecting giant cell arteritis in adults.

Key facts

Who runs it
Fondation Ophtalmologique Adolphe de Rothschild
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Status
Recruiting
People taking part
133 people, planned
Started
10 Jan 2024
Expected to end
Jun 2027
Type of study
Observational
Treatments tested
  • 3D T1 MRI sequences injected with fat saturation and black blood
Record updated
5 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults sent for an MRI with contrast dye because doctors suspect giant cell arteritis (GCA), an inflammation of arteries. It compares several MRI scan settings.

Age
Over 18 years
Sex
All
Disease stage
Suspected GCA, based on 3 major signs, or 2 major signs and 1 minor sign. Major signs: age over 50 years, new headache, jaw or tongue pain when chewing or trouble swallowing, vision problems, and a high blood inflammation test. Minor signs: tender or hard scalp or lumps, abnormal temple artery to the touch, face pain or swelling, and general signs like fever, weight loss, poor appetite or tiredness.
Earlier treatment
People cannot join if they took high-dose steroid pills or injections (>0.5mg/kg/d of prednisone) for more than 10 days.
Biomarker or test result
Sedimentation rate at 1st hour > 50 and/or CRP > 8mg/l counts as one of the major signs.

Main reasons for not taking part

  • Cancer diagnosed less than one year before joining
  • Active infection
  • Autoimmune disease, such as lupus, rheumatoid arthritis or other vasculitis
  • Cannot have an MRI
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patient over 18 years of age
  • Referred for imaging for an injected MRI for suspected GCA
  • Suspicion of GCA based on the presence of three major criteria or two major and one minor criteria defined as follows:; Major criteria: Age > 50 years; Headache of recent onset; Claudication of the jaw, tongue or swallowing disorders; Visual problems (blindness, diplopia, blurred vision - including visual accidents occurring during the first week of treatment); Sedimentation rate at 1st hour > 50 and/or CRP > 8mg/l; Minor criteria: Hypersensitivity or induration of the scalp or presence of nodules remote from the temporal artery; Temporal artery abnormalities on palpation; Facial pain or feeling of facial edema; General signs (fever >38°C, weight loss >10%, anorexia, malaise, asthenia)
  • Cconsent to participate in the study
  • Affiliated or beneficiary of a social security plan

Who cannot take part

  • Newly diagnosed malignant disease (diagnosed less than one year prior to inclusion)
  • Systemic corticosteroid therapy for more than 10 days at high dose (>0.5mg/kg/d of prednisone)
  • Active infectious disease
  • Autoimmune disease (especially but not limited to: Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, periarteritis nodosa)
  • Contraindication to MRI
  • Patient benefiting from a legal protection measure
  • Pregnant or breastfeeding woman

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries. Its incidence is estimated at 17.8/100,000 in subjects over 50 years old (and 46/100,000 in subjects over 70 years old). This disease remains a severe pathology due in particular to its vascular, ophthalmological, neurological, cardiac and aortic complications. In case of suspected CAG, management is a real therapeutic emergency. Indeed, only corticosteroid therapy started as early as possible can prevent the occurrence of these complications.

Read full original descriptionShow less

The gold standard for the diagnosis of CAG has long been the temporal artery biopsy, but imaging is now considered as a 1st line diagnostic examination for the diagnosis of CAG according to the EULAR 2018 recommendations. Notably, temporal artery MRI has excellent sensitivity and specificity for diagnosis.

However, the high diagnostic performance of MRI has been achieved by performing 3D T1 black blood and fat saturation sequences in high resolution (<0.7mm), which are not accessible in all centers in France and worldwide.

The realization of identical sequences with a lower resolution could allow a greater generalization of these sequences and improve the diagnostic management of GCA patients, including in non-expert centers.

The objective of our study is to investigate the diagnostic performance of several 3D T1 black blood and fat saturation sequences for the diagnosis of GCA.

Treatments tested

  • 3D T1 MRI sequences injected with fat saturation and black blood

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Plain-language title
Comparing MRI image sharpness for diagnosing giant cell arteritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
5 January 2026